Day 125.3 Is Tech Mahindra the New Mylan Pharma/Tech?

Voting is beautiful, be beautiful ~ vote.©

Day 165 - Hillary's Hackers, Awan Brothers Saga Deepens

Mylan, Sugarland, Javed, Sarin Gas Attacks in Aleppo, Damascus, and Idlib Dr. Tahir Javed Causes Largest Hep C outbreak in US History

Enter Montreal, the CIA's Favorite Liaison Partner, Pakistan's ISI Didn't Start Out That Way - the CIA Drew Them That Way

Giving Pakistan ISI Hacking Tools, Sarin Gas to MB, and MK Stuff Too? Enter Montreal, the CIA's Favorite Liaison Partner, Pakistan's ISI Didn't Start Out That Way - the CIA Drew

Voting is beautiful, be beautiful ~ vote.©

Medicaid Fraud In Child Welfare: Congress Cannot Regulate What Is Not Regulated

Regulation by proxy is now in the Congress!

"At least 2 EpiPens for every kid on Medicaid"
Mylan's new lobby name

Regulation falls within the purview of the Executive Branch, but since there is a congressional movement of the majority to further strip law enforcement authorities of regulatory powers, it looks like we have a bit of a problem.

The congressional majority wants the powers of rulemaking.  Great, but it has shot itself in the foot because it is, in the same breath, gutting law enforcement capabilities of compliance which leads to an increase of fraud.

The congressional minority has refused any legislative movement to regulate the child welfare industry.  Gotta fund those campaigns, ya know.

So, how can there be a push for more deregulation of an industry which has never been regulated?

So, there you have it.

In bipartisan unison, Congress is asking questions of why Mylan has, and continues, engaged in Medicaid Fraud in Child Welfare.

And I shall continue to respond with the same statement:  "Because you allow it".

Even if these congressional committees find reason to refer for further investigation, all of this could have been prevented if Congress would just do what it is supposed to do and not just focus on the politics of protecting their corporate campaign contributors.

And as for Mylan, if you were not so greedy you propbably would never have been busted.

Wyden, Pallone Question Mylan Payments to Medicaid for EpiPens

Due to Apparent Decades-Long Misclassification as a Generic Drug, EpiPen Manufacturer Could Have Received Substantially More Taxpayer Dollars than Law Allows

WASHINGTON – Senate Finance Committee Ranking Member Ron Wyden, D-Ore., and House Energy and Commerce Committee Ranking Member Frank Pallone, Jr., D-N.J., today sent a letter to Health and Human Services (HHS) Secretary Sylvia Mathews Burwell requesting additional information regarding EpiPen’s classification and rebate obligations under the Medicaid Drug Rebate Program, following revelations that Medicaid may have been grossly overpaying for the EpiPen for nearly two decades due to a misclassification by Mylan.

“These revelations are yet another example of drug makers abusing the dysfunctional, opaque drug pricing system Americans are forced to live with today,” Wyden and Pallone said. “The Medicaid drug rebate program is key to ensuring the most vulnerable have access to affordable medicine. Today we are asking if Mylan has been unfairly underpaying Medicaid for years. If this proves true, not only has Mylan been gouging family budgets through steep price hikes, but it appears they may have also been taking advantage of taxpayers through Medicaid for decades.”

As a part of the Medicaid Drug Rebate Program, pharmaceutical companies wishing to sell their products in the program are required to pay a rebate to help make their drugs more affordable. For brand-name drugs, pharmaceutical companies are required to pay to the federal government a discount that is the greater of either 23.1 percent of the Average Manufacture Price (AMP) or AMP minus the “best price” for the drug, plus an additional discount if a drug’s price increases faster than the rate of inflation. The discount for generic drugs is lower, at 13 percent of the AMP.

Recent evidence indicates that, since at least 1997, EpiPen may have been incorrectly designated by relevant pharmaceutical companies as a generic in the Medicaid program, despite being considered a brand-name drug by the Food and Drug Administration (FDA) and Medicare. This would mean Mylan has been vastly underpaying rebates owed to Medicaid for the EpiPen for years.

Wyden Pallone EpiPen Medicaid Drug Rebate Letter-Sept 2 by Beverly Tran on Scribd

Voting is beautiful, be beautiful ~ vote.©

My Questions To Help Out Senate Judiciary On Calling Out Possible Medicaid Fraud In Child Welfare With Mylan

Heather Bresch

Heather Bresch, CEO of Mylan Pharmaceuticals, has recently announced an 461% increase in the cost of EpiPens. If you ever wanted a working example of Medicaid fraud in child welfare, well, here you have it.

She recently justified the cost increase on the U.S. health care system citing price markups of the multiple layers of distribution players.

Before I set forth a series of poignant questions which, as a CEO, she failed to raise, I would like everyone to watch this video on the cost of the EpiPen in Canada.  International distribution did not change pricing.



Now, here are my questions for the U.S. Senate Judiciary Committee and Chairman Chuck Grassley:

(Q1)  Why was the announcement to raise the price made the same day Bresch made $5 million in selling off her stock of Mylan, knowing fully well, in advance, the schedule of her option was also set for the same day?

(A1)  This action was obviously strategic, but why?  At this juncture one can only guess, but I am going for the maximization of profits for "tax aversion" purposes, of course.

(Q2) Why, as an issue of corporate ethics, in the light of the Shrkeli price gouging of Daraprim scandal, would such a person take such a similar action, knowing fully well, that the targeted population are children of poverty, specifically public schools, with unfunded mandates, to be stocked with necessary medicine, billed through Medicaid?

(A2) Medicaid fraud in child welfare is an unregulated industry, pervasively woven into the fabric our national history, with no elected officials, public administrators or anyone from the legal or child welfare community willing to speak upon these well documented woes.  I assert, that, because the industry is too big to fail and the profits will eventually fund political campaigns to keep the system intact, no one will initiate movement in fear of the destruction of one's political career.

(Q3)  Has this woman, with her father a prominent Senator Joe Manchin, taken a backdoor political stance with him on the repeal of Obamacare by blaming Obamacare for the price hike in order for her father to keep his Democratic seat in the Senate in a strongly Republican-swayed presidential 2016 district made by the salacious actions of the DNC?

(A3) Sounds plausible to me.

(Q4) Is there a possible, spurious, relationship between the inversion of Mylar and the Clinton Foundation?

(A4)  Only a formal referral for federal investigation can answer this question.

(Q5)  Could this possibly be a violation of antitrust?  Let me sniff.

(A5)  Yup.  It stinks of antitrust violations.  Seek and ye shall find, my fine Senate Judiciary Staffers!

"Get 'em."

Senate Judiciary Chair Chuck Grassley Request to Heather Bresch of Mylan on EpiPen Price Increase by Beverly Tran on Scribd

#epigate #epipen

Voting is beautiful, be beautiful ~ vote.©